{"protocolSection": {"identificationModule": {"nctId": "NCT00870584", "orgStudyIdInfo": {"id": "CIGE025AUS33"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma", "officialTitle": "A 26-week Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma"}, "statusModule": {"statusVerifiedDate": "2011-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-03"}, "primaryCompletionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-03-25", "studyFirstSubmitQcDate": "2009-03-25", "studyFirstPostDateStruct": {"date": "2009-03-27", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-10-12", "resultsFirstSubmitQcDate": "2011-10-12", "resultsFirstPostDateStruct": {"date": "2011-11-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-10-12", "lastUpdatePostDateStruct": {"date": "2011-11-17", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}, "collaborators": [{"name": "Genentech, Inc.", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "This study will evaluate the effect of omalizumab on markers of impairment in patients with inadequately controlled persistent allergic asthma on Step 4 or above therapy as defined in the 2007 National Heart, Lung, and Blood Institute (NHBLI) Guidelines"}, "conditionsModule": {"conditions": ["Persistent Allergic Asthma"], "keywords": ["Asthma; asthma management; asthma impairment ; Xolair ; omalizumab"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 271, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Omalizumab", "type": "EXPERIMENTAL", "description": "The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used.", "interventionNames": ["Drug: Omalizumab"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo was administered subcutaneously every 2 weeks or every 4 weeks depending on the dosing schedule in the protocol.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Omalizumab", "description": "Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.", "armGroupLabels": ["Omalizumab"], "otherNames": ["Xolair"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Asthma Control Test (ACT) After 24 Weeks of Treatment", "description": "The Asthma Control Test (ACT) is a validated tool to assess overall asthma control over the last 4 weeks in patients aged \\>= 12 years old. It is a 1 page questionnaire consisting of 5 simple questions assessing: asthma symptoms, use of rescue medications, and the impact of asthma on everyday functioning. All questions are scored on a 5-point Likert scale, with a higher score indicating better control. All scores are added together to calculate a total score. Total score ranges from 5 to 25. A positive change indicates improvement.", "timeFrame": "Baseline and 24 weeks"}], "secondaryOutcomes": [{"measure": "Investigator Global Evaluation of Treatment Effectiveness (IGETE) at 24 Weeks", "description": "The IGETE is an assessment of asthma symptom control in response to asthma treatment. It consists of the question \"What is the investigator's overall impression of the study medication and its effect on the typical symptoms of allergic asthma during the study?\" The scale is: excellent, good, moderate, poor, and worsening. A good or excellent response is suggested as a means of defining a patient who has responded to treatment.", "timeFrame": "24 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Total Asthma Control Test (ACT) score of \u226419 plus at least one of the following in the 4 weeks preceding visit 1, on average:\n\n  * Symptoms \\> 2 days/week\n  * Night-time awakenings \u22651 time/week\n  * Short-acting beta2-agonist (SABA) use for symptom control \\>2 days/week forced expiratory volume in 1 second (FEV1) \u2264 80% predicted\n\nExclusion Criteria:\n\n* History of intubation for asthma.\n* An asthma exacerbation requiring treatment with systemic steroids within 4 weeks of screening (Visit 1).\n* Less than 3 months of stable maintenance oral corticosteroid therapy for asthma\n\nOther protocol-defined inclusion/exclusion criteria applied", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Jasper Summit Research, LLC", "city": "Jasper", "state": "Alabama", "zip": "35501", "country": "United States", "geoPoint": {"lat": 33.83122, "lon": -87.27751}}, {"facility": "Allergy Asthma and Immunology Center of Alaska", "city": "Anchorage", "state": "Alaska", "zip": "99508", "country": "United States", "geoPoint": {"lat": 61.21806, "lon": -149.90028}}, {"facility": "Medical Research of Arizona, A division of Allergy Asthma & Immunology Associates, LTD", "city": "Scottsdale", "state": "Arizona", "zip": "85251", "country": "United States", "geoPoint": {"lat": 33.50921, "lon": -111.89903}}, {"facility": "Waren W. Pleskow, MD", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "William Ebbeling, MD, Inc", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Pediatric Care Medical Group, Inc", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "California Allergy & Asthma Medical Group", "city": "Palmdale", "state": "California", "zip": "93551", "country": "United States", "geoPoint": {"lat": 34.57943, "lon": -118.11646}}, {"facility": "Allergy Associates Medical Group, Inc", "city": "San Diego", "state": "California", "zip": "92120", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Sansum Clinic", "city": "Santa Barbara", "state": "California", "zip": "93110", "country": "United States", "geoPoint": {"lat": 34.42083, "lon": -119.69819}}, {"facility": "Allergy & Asthma Clinical Research, Inc.", "city": "Walnut Creek", "state": "California", "zip": "94598", "country": "United States", "geoPoint": {"lat": 37.90631, "lon": -122.06496}}, {"facility": "Innovative Research of West Florida, Inc", "city": "Clearwater", "state": "Florida", "zip": "33756", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Palm Spring Research Institute, Inc", "city": "Hialeah", "state": "Florida", "zip": "33012", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Integrity Research, LLC", "city": "Pensacola", "state": "Florida", "zip": "32514", "country": "United States", "geoPoint": {"lat": 30.42131, "lon": -87.21691}}, {"facility": "Hugh Windom, MD, PA", "city": "Sarasota", "state": "Florida", "zip": "34233", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "South Miami Clinical Research, LLC", "city": "South Miami", "state": "Florida", "zip": "33143", "country": "United States", "geoPoint": {"lat": 25.7076, "lon": -80.29338}}, {"facility": "Georgia Pollens Clinical Research Centers, Inc", "city": "Albany", "state": "Georgia", "zip": "31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "Sneeze, Wheeze and Itch Associates, LLC", "city": "Normal", "state": "Illinois", "zip": "61761", "country": "United States", "geoPoint": {"lat": 40.5142, "lon": -88.99063}}, {"facility": "Chest Medicine Clinical Services", "city": "Skokie", "state": "Illinois", "zip": "60076", "country": "United States", "geoPoint": {"lat": 42.03336, "lon": -87.73339}}, {"facility": "Clinical Research Center of Indiana", "city": "Indianapolis", "state": "Indiana", "zip": "46208", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Kansas City Allergy & Asthma Center", "city": "Overland Park", "state": "Kansas", "zip": "66210", "country": "United States", "geoPoint": {"lat": 38.98223, "lon": -94.67079}}, {"facility": "Cotton-O'Neil Clinical Research Center", "city": "Topeka", "state": "Kansas", "zip": "66606", "country": "United States", "geoPoint": {"lat": 39.04833, "lon": -95.67804}}, {"facility": "Abraham Research, PLLC", "city": "Crescent Springs", "state": "Kentucky", "zip": "41017", "country": "United States", "geoPoint": {"lat": 39.05145, "lon": -84.58161}}, {"facility": "Rx R&D", "city": "Metairie", "state": "Louisiana", "zip": "70002", "country": "United States", "geoPoint": {"lat": 29.98409, "lon": -90.15285}}, {"facility": "Acadiana Medicine Clinic", "city": "Opelousas", "state": "Louisiana", "zip": "70570", "country": "United States", "geoPoint": {"lat": 30.53353, "lon": -92.08151}}, {"facility": "Paul A Shapero, MD", "city": "Bangor", "state": "Maine", "zip": "04401", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Chesapeake Clinical Research", "city": "Baltimore", "state": "Maryland", "zip": "21236", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Respiratory Medicine Research Institute of Michigan", "city": "Ypsilanti", "state": "Michigan", "zip": "48197", "country": "United States", "geoPoint": {"lat": 42.24115, "lon": -83.61299}}, {"facility": "Clinical Research Institute", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "The Clinical Research Center, LLC", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Montana Medical Research, Inc.", "city": "Missoula", "state": "Montana", "zip": "59808", "country": "United States", "geoPoint": {"lat": 46.87215, "lon": -113.994}}, {"facility": "Alan Kaufman, MD", "city": "Bronx", "state": "New York", "zip": "10465", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Maimonides Medical Center, Division of Pediatric Pulmonology", "city": "Brooklyn", "state": "New York", "zip": "11219", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Allergy Asthma Immunology of Rochester Research Center", "city": "Rochester", "state": "New York", "zip": "14618", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "Allergy & Asthma Center of NC, PA", "city": "High Point", "state": "North Carolina", "zip": "27262", "country": "United States", "geoPoint": {"lat": 35.95569, "lon": -80.00532}}, {"facility": "Wilmington Medical Research", "city": "Wilmington", "state": "North Carolina", "zip": "28401", "country": "United States", "geoPoint": {"lat": 34.22573, "lon": -77.94471}}, {"facility": "Allergy and Respiratory Center", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "New Horizons Clinical Research", "city": "Cincinnati", "state": "Ohio", "zip": "45242", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Oklahoma Allergy & Asthma Clinic", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73104", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Allergy, Asthma and Clinical Research Center", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Baker Allergy Asthma and Dermatology Research Center, LLC", "city": "Lake Oswego", "state": "Oregon", "zip": "97035", "country": "United States", "geoPoint": {"lat": 45.42067, "lon": -122.67065}}, {"facility": "Asthma Allergy & Pulmonary Associates", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19107", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "AAPRI Clinical Research Institute", "city": "Lincoln", "state": "Rhode Island", "zip": "02865", "country": "United States", "geoPoint": {"lat": 41.92111, "lon": -71.435}}, {"facility": "Pediatric Pulmonary Associates of North Texas, PA", "city": "Dallas", "state": "Texas", "zip": "75230", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Western Sky Medical Research", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "North Texas Institute for Clinical Trials", "city": "Fort Worth", "state": "Texas", "zip": "76132", "country": "United States", "geoPoint": {"lat": 32.72541, "lon": -97.32085}}, {"facility": "Allergy & Asthma Associates", "city": "Houston", "state": "Texas", "zip": "77054", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Lynchburg Pulmonary Associates", "city": "Lynchburg", "state": "Virginia", "zip": "24501", "country": "United States", "geoPoint": {"lat": 37.41375, "lon": -79.14225}}, {"facility": "Virginia Adult and Pediatric Allergy and Asthma PC", "city": "Richmond", "state": "Virginia", "zip": "23229", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Asthma Inc.", "city": "Seattle", "state": "Washington", "zip": "98105", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Pulmonary and Research Associates", "city": "Spokane", "state": "Washington", "zip": "99204", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "Related Info", "url": "http://www.novartisclinicaltrials.com"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Omalizumab", "description": "The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used."}, {"id": "FG001", "title": "Placebo", "description": "Placebo was administered subcutaneously every 2 weeks or every 4 weeks depending on the dosing schedule in the protocol."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "136"}, {"groupId": "FG001", "numSubjects": "135"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "120"}, {"groupId": "FG001", "numSubjects": "122"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "13"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Omalizumab", "description": "The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used."}, {"id": "BG001", "title": "Placebo", "description": "Placebo was administered subcutaneously every 2 weeks or every 4 weeks depending on the dosing schedule in the protocol."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "135"}, {"groupId": "BG002", "value": "271"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "41.9", "spread": "14.60"}, {"groupId": "BG001", "value": "40.7", "spread": "14.85"}, {"groupId": "BG002", "value": "41.3", "spread": "14.71"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "93"}, {"groupId": "BG001", "value": "87"}, {"groupId": "BG002", "value": "180"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "91"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Asthma Control Test (ACT) After 24 Weeks of Treatment", "description": "The Asthma Control Test (ACT) is a validated tool to assess overall asthma control over the last 4 weeks in patients aged \\>= 12 years old. It is a 1 page questionnaire consisting of 5 simple questions assessing: asthma symptoms, use of rescue medications, and the impact of asthma on everyday functioning. All questions are scored on a 5-point Likert scale, with a higher score indicating better control. All scores are added together to calculate a total score. Total score ranges from 5 to 25. A positive change indicates improvement.", "populationDescription": "The Full Analysis Set consisted of patients to whom study drug had been assigned through randomization. Patients inappropriately randomized were excluded from this analysis set.\n\nParticipants with observations at both baseline and 24 weeks were included in the analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline and 24 weeks", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used."}, {"id": "OG001", "title": "Placebo", "description": "Placebo was administered subcutaneously every 2 weeks or every 4 weeks depending on the dosing schedule in the protocol."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "118"}, {"groupId": "OG001", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.2", "spread": "4.37"}, {"groupId": "OG001", "value": "4.7", "spread": "4.01"}]}]}]}, {"type": "SECONDARY", "title": "Investigator Global Evaluation of Treatment Effectiveness (IGETE) at 24 Weeks", "description": "The IGETE is an assessment of asthma symptom control in response to asthma treatment. It consists of the question \"What is the investigator's overall impression of the study medication and its effect on the typical symptoms of allergic asthma during the study?\" The scale is: excellent, good, moderate, poor, and worsening. A good or excellent response is suggested as a means of defining a patient who has responded to treatment.", "populationDescription": "Full Analysis Set", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "24 weeks", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used."}, {"id": "OG001", "title": "Placebo", "description": "Placebo was administered subcutaneously every 2 weeks or every 4 weeks depending on the dosing schedule in the protocol."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}]}], "classes": [{"title": "Excellent", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "19"}]}]}, {"title": "Good", "categories": [{"measurements": [{"groupId": "OG000", "value": "44"}, {"groupId": "OG001", "value": "44"}]}]}, {"title": "Moderate", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "30"}]}]}, {"title": "Poor", "categories": [{"measurements": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "36"}]}]}, {"title": "Worsening", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Omalizumab", "description": "The determined dose (at least 0.016 mg/kg/IgE (IU/mL) was administered subcutaneously every 2 weeks or every 4 weeks. Dose and dosing interval were determined based on patient body weight and pre-treatment serum IgE level; a dosing table was used.", "seriousNumAffected": 3, "seriousNumAtRisk": 136, "otherNumAffected": 52, "otherNumAtRisk": 136}, {"id": "EG001", "title": "Placebo", "description": "Placebo was administered subcutaneously every 2 weeks or every 4 weeks depending on the dosing schedule in the protocol.", "seriousNumAffected": 5, "seriousNumAtRisk": 135, "otherNumAffected": 51, "otherNumAtRisk": 135}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Leukocytosis", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Pericarditis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Bronchitis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Infected bites", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Post procedural infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Wound infection pseudomonas", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 135}]}, {"term": "Arthropod bite", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Hyponatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 135}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 135}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 135}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 135}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 135}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 135}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 135}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 20, "numAtRisk": 136}, {"groupId": "EG001", "numAffected": 25, "numAtRisk": 135}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M413", "name": "Omalizumab", "asFound": "Enriched", "relevance": "HIGH"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}